NEW YORK STOCK EXCHANGE, INC. · MRK
+4.85% · +$5.56
Merck & Co Inc

Merck & Co Inc

Pharmaceuticals
$120.26

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
BETA

Why is MRK moving today?

Analyzing news articles + insider activity + analyst signals…
About Merck & Co Inc
PHARMACEUTICAL PREPARATIONS
Founded
Listed
1949
Employees
75K
HQ
US

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Open
$117.16
Previous close
$114.70
Day high
$120.55
Day low
$117.09
Market cap
$297.02B
IPO
1941-01-01
Country
US
Currency
USD
Data ledger
Quote and day range
As of June 4, 4:00 PM EDT
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

MRK insider activity

Merck & Co Inc

Score
Coverage building
Pressure
Net buying
Filings
94
Buys / sells
59 / 35
Net value
$320K
Insiders
26
Named filers
MS
Mayo Stephen
Insider
Leadership
SE
Seidman Christine E
Insider
Leadership
KL
Karsanbhai Surendralal Lanca
Insider
Leadership
Cluster

24 insiders bought in the last 90 days

Net pressure

Net buying: $320K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-022026-05-29Mayo StephenInsiderbuy$118.721,85314,825$220KSEC Form 4
2026-06-022026-05-29Seidman Christine EInsiderbuy$118.721,85321,228$220KSEC Form 4
2026-06-022026-05-29Karsanbhai Surendralal LancaInsiderbuy$118.721,8535,392$220KSEC Form 4
2026-06-022026-05-29Coe Mary EllenInsiderbuy$118.721,85331,766$220KSEC Form 4
2026-06-022026-05-29Rothman PaulInsiderbuy$118.721,85334,945$220KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 89 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

MRK contract awards, year to date.

Public federal awards linked to this ticker.

$361.9M
Refresh interval: 12hSource: Federal contract awards
Department of Health and Human Services
$361.3M
VACCINES FOR CHILDREN

VACCINES FOR CHILDREN

Mar 31, 2026
Department of Veterans Affairs
$342.3K
WINREVAIR 45MG/VIAL INJ,LYPHL

WINREVAIR 45MG/VIAL INJ,LYPHL

May 14, 2026
Department of Veterans Affairs
$42.8K
PHARMACEUTICAL ORDER FOR THE PUGET SOUND VA MEDICAL CENTER.

PHARMACEUTICAL ORDER FOR THE PUGET SOUND VA MEDICAL CENTER.

May 19, 2026
Department of Veterans Affairs
$22.5K
PATIENT MEDICATION OF BELZUTIFAN 40MG - ORDER PLACED FOR A PATIENT AT THE HUNTINGTON VA MEDICAL CENTER.

PATIENT MEDICATION OF BELZUTIFAN 40MG - ORDER PLACED FOR A PATIENT AT THE HUNTINGTON...

May 14, 2026
Department of Veterans Affairs
$22.5K
PHARMACY ORDER FOR VETERAN(S).

PHARMACY ORDER FOR VETERAN(S).

May 10, 2026
Lobbying spend

MRK lobbying filings, year to date.

Registered lobbying filings matched to Merck & Co Inc.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MRK in this window.
Latest news · MRK
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Loading consensus…
Options · Live
Loading options chain…
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.